Drug Makers Outsourcing To China Exposed To Safety Issues
This article was originally published in PharmAsia News
The move by multinational drug makers to outsource work to low-wage countries such as China is exposing the companies to the consequences of lax safety provisions. Safety issues in China already are causing concern in the U.S. FDA and in other countries that import its drugs. China is the world's largest producer of active pharmaceutical ingredients. The latest incident involves Baxter International and harmful side effects of its Heparin (heparin sodium), supplied by a Chinese company whose identity the FDA does not disclose. (Click here for more - a subscription may be required
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.